It should also be pointed out that other therapeutic options exist for Olmsted syndrome, in particular the recent discovery that topical application of the EGFR inhibitor erlotinib shows remarkable efficacy in managing Olmsted symptoms such as hyperkeratosis and pain, which can resolve within 3 months from the start of the therapy.37 This evidence concerns the gene EGFR and Hyperkeratosis.